want to become wealthy.

📘 Part 1. U.S.-Listed Leaders — The “Obesity Drug One-Tops” Already Making Real Money Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE ADR: NVO / Copenhagen: NOVO-B) are already generating substantial revenue and profit from GLP-1–based obesity and diabetes therapies. While many biotechs still trade on potential , these two have validated the business model. Contents Eli Lilly — Mounjaro & Zepbound Novo Nordisk — Ozempic & Wegovy U.S. Followers (Amgen, Viking) Part 2. Korea-Listed Names (Hanmi, HK inno.N, Ildong, D&D) Part 3. By the Numbers — Market & Tables Part 4. Final Framing — What to Use & What to Buy Sources When you talk about the obesity-treatment market of the 2020s, it ultimately boils down to two names: Eli Lilly and Novo Nordisk . Let’s go one by ...

📌 GLP-1 · Obesity drugs · Global economy The “Obesity Drug Revolution” and a New Global Economic Map Over three parts, we look at how GLP-1 obesity drugs (Ozempic, Wegovy, Mounjaro, Zepbound) are not only changing bodies, but reshaping healthcare costs, consumer spending, industry structure, and investment flows. Table of Contents Part 1. The “Obesity Drug Revolution” – Drugs that reshape bodies, and the economy Part 2. A “less-eating world” and the industries it disrupts Part 3. In a slimming world, where does the money flow? Part 1 📘 Part 1. The “Obesity Drug Revolution” – Drugs that reshape bodies, and the economy By the mid-2020s, one of the most frequently cited themes in global financial markets and Wall Street reports ...